News for 'INOL' - (InoLife Technologies, Inc. Announces Immediate Availability of the Cytochrome P450 2C1 Plavix Metabolizing Test to the Medical Industry)
RALEIGH, NC, Sep 08, 2010 (MARKETWIRE via COMTEX) -- InoLife Technologies, Inc.
(OTCBB: INOL), a service based healthcare products development, integration and
marketing Company, is extremely pleased that their recently presented Cytochrome
P450 2C1 test to determine a person's ability to metabolize Plavix is
immediately available to the medical industry which includes physicians,
hospitals, medical clinics, and pharmacies. Physicians are currently placing
orders on a daily basis and are incorporating the Cytochrome P450 2C1 Plavix
Metabolizing test into their patients health programs.
InoLife's Cytochrome P450 2C1 test is currently being used to identify how a
patient's genetics may affect the body's response to Plavix (Clopidogrel). The
test is available through the medical community only including physicians,
hospitals, and medical clinics. This test is not available for sale to the
general public.
According to the FDA in a press release dated March 12th, 2010 it is estimated
that 2 percent to 14 percent of the U.S. population are poor metabolizers of
certain medications. In 2009 the Federal Drug Administration approved wording on
the drug label encouraging genetic testing for DNA variants based on specific
risks. It is important to note that this drug metabolism test is not
all-inclusive and is for the physician's guidance only.
InoLife has incorporated the EasiCollect(TM) System, which combines an optimized
foam collection surface with an FTA card for collection of buccal cells and
preservation of DNA. InoLife prides itself in providing the EasiCollect(TM)
System that adheres to the strict guidelines of the Clinical Laboratory
Improvement Amendments (CLIA) that monitors approximately 200,000 laboratory
entities. The Center for Medicare & Medicaid Services regulates all laboratory
testing (except research) performed on humans in the U.S. through CLIA.
About InoLife Technologies, Inc. InoLife is poised to become one of the premier
U.S. marketers of state-of-the-art DNA-based test products. Positioned for
growth and success in a burgeoning market, InoLife Technologies,
www.inolifetech.com, is primarily focused on products, services and solutions
that will enable state-of-the-art healthcare for today and the future for a
diverse base of customers and end users. The Company's mission is to identify,
develop, integrate and bring to market innovative healthcare-based products and
services that provide timely and practical solutions. The primary products and
services that InoLife is currently addressing focuses upon those specific
products and services that provide key solutions through the innovative use of
specific DNA testing and Genetic analysis systems.
The principal customers of InoLife's products and services are healthcare
providers, physicians, practitioners, hospitals and outpatient facilities.
InoLife will be marketing and distributing its products through traditional
distribution channels. Additionally InoLife has developed certain products that
can be sold directly to consumers and has created specific programs to reach
those customers including e-commerce, direct sales, healthcare providers,
pharmacies, distributors, retail sellers and specialty retailers.
(Plavix is a trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals
Partnership.)
Forward-Looking Statements Safe Harbor Statement under the Private securities
Litigation Reform Act of 1995: The statements contained herein, which are not
historical, are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
expressed in the forward-looking statements including, but not limited to,
certain delays beyond the Company's control with respect to market acceptance of
new technologies, products and services, delays in testing and evaluation of
products and services, and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission.
AI
